agenda 2024 06 26 28 508

Final - June 26, 2024
8:00 Welcome & Introductions Dr. Keipp Talbot (ACIP Chair)
Dr. Melinda Wharton (ACIP Executive Secretary, CDC)
8:30 Respiratory Syncytial Virus Vaccines - Adult
Introduction Dr. Camille Kotton (ACIP, WG Chair)
Abrysvo (Pfizer) safety and immunogenicity in non-pregnant adults
aged 18-59 yearsDr. Iona Munjal (Pfizer)
Arexvy (GSK) immunogenicity with a 24-month revaccination interval Dr. Susan Gerber (GSK)
mRNA-1345 (Moderna) Update on vaccine safety, efficacy and
revaccination dataDr. Rituparna Das (Moderna)
Postmarketing safety updates: Vaccine Safety Datalink Dr. James Donahue (Marshfield Clinic Research Institute)
Evaluation of Guillain-Barre Syndrome (GBS) following RSV
vaccination among adults 65 years and olderDr. Patricia Lloyd (FDA)
10:00 Break
10:10 RSV Vaccines - Adult (continued)
Observational RSV vaccine effectiveness Dr. Diya Surie (CDC, NCIRD)
Economic analysis of adult RSV vaccination Dr. David Hutton (University of Michigan)
Update to benefits and risks discussion Dr. David Hutton (University of Michigan)
Comparison of economic analyses of adult RSV vaccination Dr. Ismael Ortega-Sanchez (CDC/NCIRD)
11:30 Break
11:40 RSV Vaccines - Adult (continued)
Evidence to Recommendations Dr. Michael Melgar (CDC/NCIRD), Lauren Roper
(CDC/NCIRD), Dr. Amadea Britton (CDC/NCIRD)
Clinical Considerations Dr. Michael Melgar (CDC/NCIRD)
1:05 Break
1:50 Combined Diphtheria and Tetanus Toxoids and Acellular Pertussis,
Inactivated Poliovirus, Haemophilus influenzae Type B Conjugate,
and Hepatitis B vaccine (Vaxelis®)
Introduction Dr. Jamie Loehr (ACIP, WG Chair)
EtR and proposed recommendations: Use of Vaxelis among American
Indian and Alaska Native InfantsDr. Jennifer Collins (CDC/NCIRD)
Updated VFC resolution Dr. Jeanne Santoli (CDC/NCIRD)
2:50 Break
3:00 Public Comment
3:20 VOTES
Respiratory Syncytial Virus (RSV) Vaccines Votes Dr. Michael Melgar (CDC/NCIRD)
Vaxelis Dr. Jennifer Collins (CDC/NCIRD)
Vaxelis VFC Dr. Jeanne Santoli (CDC/NCIRD)
4:10 Break
4:20 Chikungunya Vaccine
Introduction Dr. Wilbur Chen (ACIP, WG Chair)
Update on chikungunya vaccines Dr. Susan Hills (CDC/NCEZID)
Epidemiology of chikungunya in U.S. territories and states Dr. Susan Hills (CDC/NCEZID)
Cost-effectiveness of use of live attenuated chikungunya vaccine
among adults living in U.S. territories Dr. Kelly Kilburn, Dr. Erin Staples (CDC/NCEZID)
Next steps for Work Group Dr. Susan Hills (CDC/NCEZID)
5:20 Dengue Vaccines
Dengvaxia discontinuation Dr. Nicholas Bergren (Sanofi)
Dengue vaccine updates Dr. Joshua Wong (CDC/NCEZID)
5:30 RecessMEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)
Centers for Disease Control and Prevention
Atlanta, Georgia 30329
June 26-28, 2024
Wednesday, June 26, 2024
Final - June 26, 2024
8:00 Welcome & Introductions Dr. Keipp Talbot (ACIP Chair)
Dr. Melinda Wharton (ACIP Executive Secretary, CDC)
8:15 Agency Updates CDC, CMS, FDA, HRSA, IHS, OIDP, NIH
8:35 COVID-19 Vaccine
Introduction Dr. Matt Daley (ACIP, WG Chair)
COVID-19-associated hospitalizations Dr. Fiona Havers (CDC/NCIRD)
COVID-19 vaccine effectiveness update Dr. Ruth Link-Gelles (CDC/NCIRD)
Vaccine safety update for 2023-2024 COVID-19 vaccine Dr. Jonathan Duffy (CDC/NCEZID)
Economic analysis of COVID-19 vaccination Dr. Lisa Prosser (University of Michigan)
EtR for use of the 2024-2025 COVID-19 vaccine Dr. Lakshmi Panagiotakopoulos (CDC/NCIRD)
COVID-19 vaccine implementation Dr. Shannon Stokley (CDC/NCIRD)
11:05 Break
11:20 Influenza Vaccines
Introduction Dr. Jamie Loehr (ACIP, WG Chair)
Influenza A (H5N1) Update Dr. Vivien Dugan (CDC/NCIRD)
12:00 Break
1:00 Influenza Vaccines (continued)
WG Considerations and Proposed Recommendations Dr. Lisa Grohskopf (CDC/NCIRD)
2:00 Pneumococcal Vaccines
Introduction Dr. Jamie Loehr (ACIP, WG Chair)
Economic analysis and public health impact of PCV21 use in adults Dr. Charles Stoecker (Tulane University)
Comparison of economic analysis on PCV21 use in adults Dr. Andrew Leidner (CDC/NCIRD)
Summary of WG Interpretation of EtR and policy options on PCV21
use in adultsDr. Miwako Kobayashi (CDC/NCIRD)
Clinical considerations for PCV21 use in adults Dr. Miwako Kobayashi (CDC/NCIRD)
3:55 Break
4:10 Public Comment
4:30 VOTES
COVID-19 Dr. Megan Wallace (CDC/NCIRD)
Pneumococcal Dr. Miwako Kobayashi (CDC/NCIRD)
Influenza Dr. Lisa Grohskopf (CDC/NCIRD)
5:15 Recess
8:30 Welcome & Introductions Dr. Keipp Talbot (ACIP Chair)
Dr. Melinda Wharton (ACIP Executive Secretary, CDC)
8:55 Meningococcal Vaccines
Introduction Dr. Jamie Loehr (ACIP, WG Chair)
Epidemiology Updates Ms. Amy Rubis (CDC/NCIRD)
GSK Pentavalent Vaccine Immunogenicity and Safety Dr. Wendy Sohn (GSK)
WG Considerations Regarding MenABCWY Vaccine and Discussion of
Potential Risk Groups for MenB VaccinationDr. Sarah Schillie (CDC/NCIRD)
10:00 Break
10:15 Respiratory Syncytial Virus Vaccines - Maternal/Pediatric
Introduction Dr. Sarah Long (ACIP, WG Chair)
Implementation and uptake of nirsevimab and maternal RSV vaccine Dr. Shannon Stokley (CDC/NCIRD)
Maternal RSV vaccine safety surveillance Dr. Pedro Moro (CDC/NCEZID)
Summary of effectiveness of nirsevimab in infants Dr. Amanda Payne (CDC/NCIRD)
Work Group considerations Dr. Jefferson Jones, Dr. Katherine Fleming-Dutra
(CDC/NCIRD)
11:40 Human papillomavirus Vaccines
Announcement of formation of an ACIP HPV vaccines work group Dr. Oliver Brooks (ACIP, WG Chair)
11:50 AdjournFriday, June 28, 2024Thursday, June 27, 2024
Final - June 26, 2024
Acronyms
CDC Centers for Disease Control and Prevention
CMS Centers for Medicare and Medicaid Services
COVID-19 Coronavirus disease 2019
EtR Evidence to Recommendations Framework
FDA Food and Drug Administration
GRADE Grading of Recommendations Assessment, Development and Evaluation
HRSA Health Resources and Services Administration
HPV Human papillomavirus
IHS Indian Health Service
NCHHSTP National Center for HIV, Hepatitis, STD and TB Prevention
NCIRD National Center for Immunization & Respiratory Diseases
NCEZID National Center for Emerging and Zoonotic Diseases
NIAID National Institute of Allergy and Infectious Diseases
OIDP Office of Infectious Disease and HIV/AIDS Policy
RSV Respiratory Syncytial Virus (RSV)
SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus 2
WG Work Group
WHO World Health Organization
VE Vaccine Effectiveness

Summary: Final - June 26, 2024 8:00 Welcome & Introductions Dr. Keipp Talbot (ACIP Chair) Dr. Melinda Wharton (ACIP Executive Secretary, CDC) 8:30 Respiratory Syncytial Virus Vaccines - Adult  Introduction Dr. Camille Kotton (ACIP, WG Chair) Abrysvo (Pfizer) safety and immunogenicity in non-pregnant adults  aged 18-59 yearsDr. Iona Munjal (Pfizer) Arexvy (GSK) immunogenicity with a 24-month revaccination interval Dr. Susan Gerber (GSK) mRNA-1345 (Moderna) Update on vaccine safety, efficacy and …